Small RNAs have emerged as important regulators in recent years. Small RNAs have significant functions in many cellular processes including development, cell differentiation and apoptosis, and have been implicated in many diseases. BGI’s small RNA sequencing and bioinformatics analysis services provide reliable detection and profiling of small RNAs rapidly and cost effectively.

Benefits:

1. Detection of virtually all small RNAs, repeat associated small RNAs, and degraded tags of exons and introns
2. Wide range of transcript detection from two to several hundred thousand copies
3. Detection of known miRNAs; prediction and detection of novel miRNAs
4. Target gene prediction and function annotation
5. High throughput reads: more than 8 million per single-pass sequencing
6. High resolution: capable of discriminating single-base difference

Customer Testimonials:

"BGI offered a good price and the shortest turnaround time… The advanced bioinformatics service helped a lot in the data evaluation… During the process and even after finishing the project, the staff always responded quickly to our questions. The data allowed us to discover several differentially expressed miRNA and also novel miRNAs… BGI provides a world-class service and we will continue our project with their help, sequencing another 20 miRNA libraries” Dr. Marcelo Menossi, University of Campinas

MicroRNA Expression Signatures of Bladder Cancer Revealed by Deep Sequencing. PLoS One. 28 Mar 2011. 6(3):e18286.

MicroRNAs (miRNAs) are a class of small noncoding RNAs that regulate gene expression. They are aberrantly expressed in many types of cancers. In this study, we determined the genome-wide miRNA profiles in bladder urothelial carcinoma by deep sequencing. We detected 656 differentially expressed known human miRNAs and miRNA antisense sequences (miRNA*s) in nine bladder urothelial carcinoma patients by deep sequencing. Many miRNAs and miRNA*s were significantly upregulated or downregulated in bladder urothelial carcinoma compared to matched histologically normal urothelium.

Characterization of microRNAs in Serum: a Novel Class of Biomarkers for Diagnosis of Cancer and Other Diseases. Cell Res. 18 Oct 2008: 997–1006.

Dysregulated expression of microRNAs (miRNAs) in various tissues has been associated with a variety of diseases, including cancers. Here we demonstrate that miRNAs are present in the serum and plasma of humans and other animals such as mice, rats, bovine fetuses, calves, and horses. The levels of miRNAs in serum are stable, reproducible, and consistent among individuals of the same species. Employing Solexa, we sequenced all serum miRNAs of healthy Chinese subjects and found over 100 and 91 serum miRNAs in male and female subjects, respectively. We also identified specific expression patterns of serum miRNAs for lung cancer, colorectal cancer, and diabetes, providing evidence that serum miRNAs contain fingerprints for various diseases.

Bioinformatics Analysis:

1. Target prediction of novel and known miRNAs
2. Identify base editing of known miRNAs
3. GO classification and pathway enrichment analysis
4. Intersample differential expression analysis and cluster analysis of known miRNAs.

Sample Requirements:

For the Total RNA samples you will provide us:

1. Purity: OD260/280=1.8-2.2; for animal samples: RNA 28S: 18S >1.5, RIN ≥7.0
2. Concentration: For general requirements: ≥200 ng/μl; for plasma/serum or used for co-IP: concentration ≥ 5ng/μl. For <200nt small RNA isolated from mirVana^TM miRNA Isolation Kit supplied: concentration ≥20 ng/μl.
3. Sample Quantity: general requirements: total RNA ≥10 μg. For plasma/serum or used for co-IP: total RNA ≥100ng (≥5mL for serum sample); for <200nt small RNA isolated from mirVana^TM miRNA Isolation Kit: RNA ≥1ug.

Technologies

FAQ